Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical publishes prospectus regerading preferential rights issue at SEK 37 million

Regulatory information

The Board of Directors of Hansa Medical AB (publ) have prepared a prospectus in Swedish only regarding the forthcoming issue of new shares. The issue of new shares will enable phase II-trials with the drug candidate IdeS in kidney transplantation. The Prospectus has today on the 19th of March 2014 been approved and registered with the Swedish Financial Supervisory Authority in accordance with the Financial Instruments Trading Act (1991:980).

The prospectus is available via the company’s website,, and via Remium Nordic AB’s website, and will be available via the Swedish Financial Supervisory Authority website,